[Antifibrotic effects of aldehyde dextran modified superoxide dismutase in experimental silicosis].
The present paper dwells on biomedical study of aldehyde dextran modified superoxide dismutase. Pharmacokinetic data demonstrated that modification of superoxide dismutase increased its half-time. A rat model of experimental silicosis showed that aldehyde dextran modified superoxide dismutase inhibited evolving fibrosis in the lungs. The same dose of native enzyme produced no therapeutic effect. Thus, superoxide dismutase can be considered as a potential agent for treatment of fibrosis due to its modification.
Maksimenko
A V
AV
Grigor'eva
E L
EL
Bezrukavnikova
L M
LM
Petrov
A D
AD
Tishchenko
E G
EG
Arkhipova
O G
OG
Torchilin
V P
VP
D000447:Aldehydes / Q000494:pharmacology*; D000818:Animals; D003911:Dextrans / Q000494:pharmacology*; D006207:Half-Life; D008297:Male; D051379:Mice; D011658:Pulmonary Fibrosis / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains; D012829:Silicosis / Q000188:drug therapy*; D013482:Superoxide Dismutase / Q000187:drug effects / Q000378:metabolism / Q000627:therapeutic use*
D000447:Aldehydes; D003911:Dextrans; D013482:Superoxide Dismutase
Antifibroznoe deĭstvie modifitsirovannoĭ al'degiddekstranom superoksiddismutazy pri éksperimental'nom silikoze.